Cocrystal Pharma Inc (COCP)

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a...

Form EFFECT - Notice of Effectiveness

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report